Realm Therapeutics - Director/PDMR Shareholding

December 15, 2017
RNS Number : 4271Z
Realm Therapeutics PLC
15 December 2017
 

Realm Therapeutics plc

("Realm Therapeutics", "Realm" or the "Company")

 

Grant of Options

 

15 December 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, announces the grant of 2,080,000 share options to its directors and senior management to subscribe for ordinary shares of 10p each in the capital of the Company (the "Options"), as detailed below.  All Options were granted on 13 December 2017 (the "Grant Date"), have an exercise price of 38.5 pence each and a ten-year term.

 

Grants to Executive Directors vest one-third per year on each of the first three anniversaries of the Grant Date on the basis of attainment of certain key performance measures relating to clinical development and other strategic targets, which will be evaluated on the relevant anniversaries.  Grants to the Chief Medical Officer and Non-Executive Directors vest one-third per year on each of the first three anniversaries of the Grant Date.

 

Grants made to Executive Directors under the Realm Therapeutics plc Executive Omnibus Incentive Plan 2016 (the "Plan") are noted below.

 

Name

Number of Options Granted

Alex Martin (Chief Executive Officer)

830,000

Marella Thorell (Chief Financial & Operating Officer)    

350,000

In addition, Christian Peters (Chief Medical Officer) has been granted 350,000 options.

 

Grants made to Non-Executive Directors, under individual agreements which are subject to the provisions of the Plan, are noted below.  Mr. Zweifach's grant relates to his initial appointment to the Board.

 

Name

Number of Options Granted

Charles Spicer (Non-Executive Chairman)

100,000

William Birkett (Senior Independent Non-Executive Director)

100,000

Balkrishan (Simba) Gill (Non-Executive Director)

100,000

Ivan Gergel (Non-Executive Director)

100,000

Sanford (Sandy) Zweifach (Non-Executive Director)

150,000

 

Following the above grants there is a total of approximately 11.4 million options over ordinary shares outstanding which represents approximately 9.8% of the current issued share capital of the Company.

 

Contact:

Realm Therapeutics plc

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

Outside US:  +44 (0) 20 3727 1000

US:  +1 212 600 1902

 

Argot Partners

Stephanie Marks

+1 212 600 1902

 

FTI Consulting

Simon Conway / Mo Noonan

+44 (0) 20 3727 1000

 

N+1 Singer (Nominated Adviser and Broker) 

Aubrey Powell / Jen Boorer

+44 (0) 20 7496 3000

 

About Realm Therapeutics

 

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programs, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.  

 

 

Additional Disclosure

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

 

1

Details of the person discharging managerial responsibilities/person closely associated with them

a)

Name

1.   Alex Martin

2.   Marella Thorell

3.   Christian Peters

4.   Sanford (Sandy) Zweifach

5.   Charles Spicer

6.   William Birkett

7.   Balkrishan (Simba) Gill

8.   Ivan Gergel

2

Reason for notification

a)

Position/status

1.   Chief Executive Officer

2.   Chief Financial & Operating Officer

3.   Chief Medical Officer

4.   Non-Executive Director

5.   Non-Executive Chairman

6.   Senior Independent Non-Executive Director

7.   Non-Executive Director

8.   Non-Executive Director

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Realm Therapeutics PLC

b)

LEI

n/a

4

Details of the transaction(s):  section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares in Realm Therapeutics PLC

ISIN:  GB00B3XBCR18

b)

Nature of transaction

Grant of options over 2,080,000 shares under the Realm Therapeutics plc Executive Omnibus Incentive Plan 2016 and individual agreements

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1.   38.50 pence

 

2.   38.50 pence

 

3.   38.50 pence

 

4.   38.50 pence

 

5.   38.50 pence

 

6.   38.50 pence

 

7.   38.50 pence

 

8.   38.50 pence

 

830,000

 

 

 

350,000

 

350,000

 

 

 

150,000

 

 

100,000

 

 

100,000

 

 

100,000

 

 

100,000

d)

Aggregated information

· Aggregated volume

· Price

n/a

(Single transaction for each recipient of options)

e)

Date of the transaction

13 December 2017

f)

Place of the transaction

Outside a trading venue

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFLDFILSLID

Search Investor Relations